drugset / Trial / NCT06617286
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Phase 1/2
Not yet recruiting
21 enrolled
New York Medical College
University of North Carolina · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2039-12-31
- Completion
- 2040-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD30 CAR T-cell | Cell therapy | 1e+08 unknown | — |
| Subject | CD30 CAR T-cell | Cell therapy | 2e+08 unknown | — |